Arif Tasleem, Dorjay Konchok, Adil Mohammad, Sami Marwa
Department of Dermatology, STDs and Leprosy, Jawaharlal Nehru Medical College (JNMC), Aligarh Muslim University (AMU), Aligarh, India, Al-Rahman Apartment, ground floor, Behind Zakaria market, New Sir Syed Nagar, Civil lines Aligarh. India.
Department of Dermatology, Jawaharlal Nehru Medical College (JNMC), Aligarh Muslim University (AMU), Aligarh, India.
Curr Clin Pharmacol. 2017;12(1):31-35. doi: 10.2174/1574884712666170310111125.
Androgenetic alopecia is a common condition characterized by thinning of scalp hair. Conversion of testosterone to dihydrotestosterone, a more potent androgen, by the enzyme 5-α-reductase is responsible for underlying pathogenesis. Dutasteride, a synthetic 4-azasteroid, is a selective and competitive inhibitor of both type-1 and type-2 isoenzymes of 5-α-reductase. Finasteride and minoxidil are the only approved drugs for androgenetic alopecia. Dutasteride has been demonstrated to be effective in several randomized, double-blind, placebo controlled trials in androgenetic alopecia. In this review, after the pharmacology of dutasteride, the authors have discussed the status of dutasteride in androgenetic alopecia and have compared its efficacy with that of finasteride.
This article aims to review the current status of dutasteride in androgenetic alopecia. The structure, mechanism of action, pharmacokinetics and side effects are discussed along with its comparison with finasteride in androgenetic alopecia.
The main sources of our information were Medline Pubmed, Google scholar and Scopus including original articles and review articles. The keywords 'dutasteride', 'dutasteride in androgenetic alopecia' were used for search.
Like finasteride, dutasteride is now becoming popular treatment option in AGA, due to its good response shown by various randomized control studies and meta-analysis. Also, in most of these studies, dutasteride was found to be better than finasteride with comparable adverse effects. Therefore, dutasteride could become a treatment of choice for AGA in near future.
雄激素性脱发是一种常见病症,其特征为头皮毛发稀疏。睾酮通过5-α还原酶转化为更强效的雄激素双氢睾酮是其潜在发病机制。度他雄胺是一种合成的4-氮杂甾体,是5-α还原酶1型和2型同工酶的选择性竞争性抑制剂。非那雄胺和米诺地尔是仅有的被批准用于治疗雄激素性脱发的药物。在多项雄激素性脱发的随机、双盲、安慰剂对照试验中,度他雄胺已被证明有效。在本综述中,作者在介绍度他雄胺的药理学之后,讨论了其在雄激素性脱发中的应用现状,并将其疗效与非那雄胺进行了比较。
本文旨在综述度他雄胺在雄激素性脱发中的应用现状。文中讨论了其结构、作用机制、药代动力学和副作用,并将其与非那雄胺在雄激素性脱发中的应用进行了比较。
我们的主要信息来源是Medline Pubmed、谷歌学术和Scopus,包括原创文章和综述文章。使用关键词“度他雄胺”、“度他雄胺在雄激素性脱发中的应用”进行检索。
与非那雄胺一样,由于各种随机对照研究和荟萃分析显示出良好疗效,度他雄胺目前正成为雄激素性脱发的一种流行治疗选择。此外,在大多数这些研究中,度他雄胺被发现优于非那雄胺,且不良反应相当。因此,度他雄胺在不久的将来可能会成为雄激素性脱发的首选治疗药物。